We observed that in tumor tissues, the combination treatment [ADU-S100 (20 μg) + CpG ODN (20 μg)] upregulated the expression level of IFN-β, IL-12, and TNF-α in a synergistic manner compared with the other treatments (Figures 2A–E). The gene discussed is IFNB1; the disease is neoplasm.